Brief: Ascletis Says Filing Of U.S. IND For Oral PD-L1 Small Molecule Inhibitor For Treatment Of Advanced Solid Tumors
10/01/2022 24:34
Jan 9 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES U.S. IND FILING FOR IN-HOUSE DEVELOPED
ORAL
PD-L1 SMALL MOLECULE INHIBITOR ASC61 FOR TREATMENT OF ADVANCED
SOLID TUMORS
Source text for Eikon: ID:nPnf5Wpca
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026